• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CFFT grants Savara Pharmaceuticals $1.7 million award

CFFT grants Savara Pharmaceuticals $1.7 million award

October 18, 2013
CenterWatch Staff

Savara Pharmaceuticals has received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics(CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation. The award will advance the development of AeroVanc, the first inhaled antibiotic being developed to treat the increasing number of people with cystic fibrosis (CF) who have persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection.

"The support of the CF Foundation is yet another acknowledgment that AeroVanc addresses an unmet need for people with CF suffering from MRSA infection," said Rob Neville, CEO of Savara Pharmaceuticals. "The $6 million in support that Savara has received from the CF Foundation and the NIH provides critical funding to advance the AeroVanc program.”

Savara is now enrolling patients for its phase II trial of AeroVanc. It is a randomized, double-blind, placebo-controlled study in 80 CF patients with persistent MRSA lung infection, and is being conducted at 26 CF centers nationwide. The primary objective of the study is to evaluate the efficacy of AeroVanc in reducing the quantity of MRSA colony forming units in sputum cultures. The secondary objectives include evaluation of the safety of repeat dosing with AeroVanc and the efficacy of AeroVanc in improving lung function, reducing respiratory symptoms, and prolonging the time to pulmonary exacerbations and the need for other antibiotics.

"Savara's AeroVanc is a much needed investigational product, as none of the current inhaled antibiotics address the growing problem of MRSA infection," said Dr. Bonnie W. Ramsey, director of the Center for Clinical and Translational Research at Seattle Children's Research Institute, and one of the lead investigators of TOBI, an inhaled form of tobramycin used to treat chronic Pseudomonas aeruginosa infection in CF. "TOBI has become the cornerstone of treatment in CF, and AeroVanc has the potential to become analogous to TOBI for MRSA."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing